A r t i c l e s Mapping the functional relationships between genes is a critical step toward understanding how disease states arise from gene dysfunction [1] [2] [3] . In yeast, high-throughput methods have enabled the creation of genetic networks, with 23 million double mutants identifying nearly 1 million interactions 4 . Network complexity is orders of magnitude greater in human cells, with about tenfold more pairwise combinations of protein-coding genes and thousands of distinct cell types in which to examine interactions.
We developed an approach that relies on orthogonal Cas9 enzymes, from S. pyogenes and S. aureus (SpCas9 and SaCas9), to overcome practical limitations of previous approaches and to achieve dualknockout efficiencies that enable robust screening. This approach uncovers synthetic lethal and buffering relationships across multiple cell types with excellent correspondence between unique sgRNA pairs targeting the same gene pairs. As two sgRNAs independently program two different Cas9s, this approach can combine different activities in the same screen, such as knockout and overexpression (CRISPRa) 15 . We anticipate that screens to interrogate large combinatorial space at scale (dubbed Big Papi screens) will have widespread application in many cellular models.
RESULTS

Generating double knockouts using a dual Cas9 system
We aimed to develop a system with maximal on-target efficiency at two independent genomic sites, postulating that using two independent Cas9 enzymes would mitigate several sources of inefficiency ( Supplementary  Fig. 1 ). We designed a lentiviral construct, pPapi, to express SaCas9 and two sgRNAs from the U6 and H1 promoters (Fig. 1a) . A flow cytometry assay assessed dual targeting of EGFP and endogenous CD81 in A375 cells engineered to stably express SpCas9 and EGFP, and we measured the effect of varying the promoter and Cas9 ortholog employed by each sgRNA. Partnering SaCas9 and SpCas9 sgRNAs achieved dual knockout in 50-87% of cells with 4 different combinations of sgRNAs ( Fig. 1b and Supplementary Fig. 2 ), indicating a potential for high efficiency.
A r t i c l e s
To enable efficient construction of pooled, multiplex libraries, we developed a cloning scheme with synthesized oligonucleotides (~140 nt), overlap extension, and a single transformation step of Escherichia coli (Fig. 1a) . A pool consisting of M SpCas9 sgRNAs and N SaCas9 sgRNAs, a total of M + N oligos, generates a pool comprising M × N pairwise combinations. We generated a Synthetic Lethal (SynLet) library, described below, with 96 unique sgRNAs cloned into each position, totaling 96 2 = 9,216 dual-sgRNA elements. The proximity of the sgRNAs permits them to be amplified and sequenced together in a single NextGen sequencing read. The cumulative distribution function for the pool had an area-under-the-curve (AUC) of 0.62 (Fig. 1c) , comparable to our previously described Brunello genome-wide library (AUC of 0.64; AUC = 0.5 for a perfectly uniform distribution) 16 . We compared this SynLet library to four other published libraries [6] [7] [8] 17 , which all rely on two transformation steps into E. coli; AUCs for these libraries ranged from 0.68-0.77. Likewise, for the SynLet library, 79% of sgRNA pairs were found in the top 90% of reads, whereas the other four libraries showed more attrition, capturing 53-70% of elements at this threshold (Fig. 1c) .
Optimizing sgRNA design for SaCas9
Previously, we determined rules to predict high-performing SpCas9 sgRNAs by coupling experimentation with machine learning 16, 18 . We took a similar approach to optimize the design of SaCas9 sgRNAs. We developed a SaCas9 version of lentiCRISPR-v2, replacing the SpCas9 and tracrRNA scaffold with their S. aureus counterparts. We designed a pooled tiling library to compare SpCas9 and SaCas9 by targeting EEF2, a common essential gene, with all possible sgRNA sequences regardless of protospacer adjacent motif (PAM), and assayed activity by a viability screen in A375 cells. As expected for SpCas9, the set of sgRNAs using an NGG PAM (n = 449) were depleted compared to those using all other PAMs (n = 4,087), with a median log 2 -foldchange of −2.5 relative to the plasmid DNA (Fig. 2a) . For SaCas9, some sgRNAs with an NNGRRV PAM (n = 349; R = A or G; V = A, C, or G) were active, but as expected 19, 20 , NNGRRT (n = 47) was most active, with a median log 2 -fold-change of −4.3. We compared sgRNAs sharing a common cut site between SaCas9 and SpCas9, and observed that SaCas9 typically had higher activity (Fig. 2b) .
We designed a second tiling library with all sgRNAs with an NNGRR PAM that targeted nine genes with known phenotypes in viability and drug resistance assays, a total of 5,327 sgRNAs, including controls ( Supplementary Fig. 3a) . We performed viability screens in three cell lines (A375, 293T, MOLM13), and screened relevant cell lines for 6-thioguanine (A375, 293T) and vemurafenib resistance (A375). We observed the expected activities for sgRNAs targeting these nine genes ( Supplementary Fig. 3b and Supplementary Table 1 with consistent performance across the three cell lines (Fig. 2c) , suggesting that predictive sequence features are likely to generalize across cell types.
We first used a classification model to determine sequence features correlated with high activity, examining all single-and dinucleotides 16 . The feature most predictive of high activity was thymine immediately 3′ of the core PAM sequence, NNGRR (Fig. 2d) . However, thymine is neither necessary nor sufficient for high activity: of 1,805 sgRNAs targeting viability genes in A375 cells, a non-thymine nucleotide was present in 58% of the top quintile of most-active sgRNAs, whereas 14% of sgRNAs with thymine scored in the bottom half of activity. In the RR portion of the PAM, we observed that AG is favored over other combinations of purines.
To improve predictions, we used gradient-boosted regression trees on the rank-transformed activity values 16 . Features included positionspecific and position-independent single-and dinucleotides, and thermodynamic properties; position-specific dinucleotides proved the most important for predicting activity (Fig. 2e) . To illustrate performance, we used a version of the model in which EEF2 sgRNAs were held out of the training set, and compared the predicted scores to the measured activities in A375 cells, observing a Spearman correlation of 0.64 (Fig. 2f) . Whereas high-scoring sgRNAs (score > 0.6) represent only 12% of all EEF2 sgRNAs, they are quite likely to be active, with 77% resulting in a greater than fourfold decrease in viability (Fig. 2g) . Downsampling the number of genes used for training indicated diminishing returns for model parameter estimation with nine genes (Fig. 2h) . The model A r t i c l e s developed here for SaCas9 sgRNA design, available online (http://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design) will enable more effective application of CRISPR technology.
Combinatorial gene targeting using a dual Cas9 system We first tested the Big Papi approach by screening for synthetic lethal gene combinations. As few such relationships have been validated across many cell lines, we assembled an ad hoc list of target genes (Supplementary Table 2 ). BRCA and PARP genes have a clinically appreciated synthetic lethal relationship 21, 22 . Likewise, for anti-apoptotic genes, the ability of expression of one to rescue inhibition of another is well-documented, necessitating combinatorial targeting 23 .
We also selected gene families with known or potential redundancy in their function, including MAPKs, AKTs, and ubiquitins [24] [25] [26] . Finally, we included several genes computationally predicted to engage in multiple synthetic lethal interactions 27 . We designed three sgRNAs against these 25 genes for both SaCas9 and SpCas9 (Supplementary Table 2 Cells were transduced at low multiplicity of infection (MOI; ~0.5) in biological duplicate, selected with puromycin, and cultured for 21 d; for some, an earlier time point was also collected (Fig. 3a) . We prepared genomic DNA, PCR-amplified the dual-sgRNA cassette, and quantitated library distribution by sequencing (Supplementary Table 3) . We compared abundance at day 21 to the starting abundance (plasmid DNA) to determine the effect of each sgRNA pair on viability. Independent infection replicates were well correlated for all six cell lines (Pearson correlations of 0.89-0.98, Fig. 3b ). We performed this same analysis for three other dual-knockout combinatorial studies, and found that replicate reproducibility was high for the CRISPRbased double knockout (CDKO) screen (0.98) low for the CombiGem (0.2) and Shen-Mali (0.21-0.42) screens (Fig. 3b) .
Our orthologous Cas9 approach seeks to diminish competition between two sgRNAs, which may arise from differences in transcription, RNA stability, or binding affinity to Cas9 ( Supplementary  Fig. 1 ). We compared performance of individual targeting sgRNAs in one position when partnered with varying control sgRNAs in the second position (Fig. 3c) . For targeting sgRNAs using either Cas9, the average log 2 -fold-changes were well-correlated regardless of the control sgRNA (Fig. 3d) . In contrast, the effects of individual sgRNAs paired with different controls in the CombiGEM and ShenMali libraries were not well-correlated (Fig. 3d) . The CDKO library, after removing 31% of sgRNA combinations (read counts below 50), showed much better correlation but the decreased consistency for sgRNAs driven from the mouse U6 promoter, evident in the unfiltered data, remained apparent in the filtered data (Fig. 3d) . The Shen-Mali data showed the same trend, suggesting that lower expression from the mouse U6 promoter results in unequal competition for Cas9, an issue avoided by the dual-Cas9 approach. We next examined phenotypic consistency at the gene level between the two Cas9s and observed good agreement, with Pearson correlations of 0.80-0.89 across the six cell lines (Supplementary Fig. 4a ). Combining measurements from both Cas9s, single knockouts of EEF2, CHEK1, MTOR, and WEE1 consistently exhibited viability effects, with stronger depletion at day 21, consistent with their classification as fitness genes 28 ; other genes showed cell-line-specific viability effects ( Fig. 3e and Supplementary Fig. 4b ). Thus, SaCas9 and SpCas9 produced mutually consistent knockout phenotypes across cell lines.
We next assessed synthetic lethal and buffering relationships. We modeled the expected log 2 -fold-change from sgRNA pairs as the sum of the log 2 -fold-change (LFC) for each individual sgRNA when partnered with controls, and then calculated the difference (dLFC) by comparing this expectation to the measured value ( Supplementary  Fig. 5a ). A positive dLFC represents a buffering relationship and a negative dLFC represents synthetic lethality. The measured data matched the expectation of this model well (Pearson correlation = 0.97), suggesting this is an effective metric for gene interaction (Fig. 4a) . We combined information for multiple sgRNA pairs targeting the same gene pairs, and performed the same calculations with randomized input data to generate a null distribution, allowing the calculation of a false discovery rate (FDR, Supplementary  Fig. 5b and Supplementary Fig. 5c ). Using this framework, we analyzed all six cell lines harvested at the day 21 time point ( Fig. 4b and Supplementary Table 4) .
Examining interactions within the pre-defined gene groups, several expected synthetic lethal relationships emerge (Fig. 4c) . For example, the anti-apoptotic genes BCL2L1 (Bcl-xL) and MCL1 scored strongly (FDR < 0.01) in five of six cell lines, with 12 of the 18 sgRNA combinations depleted more than two s.d. from the log 2 -fold-change of the individual sgRNAs when paired with controls in Meljuso cells (Fig. 4d) . The CDKO approach also found this interaction with strong statistical significance in the filtered data ( Supplementary Fig. 6 ) 8 . In the CombiGEM and Shen-Mali screens, few sgRNA pairs exceeded two s.d. versus control pairings, and sets of all sgRNA pairings for the top hit gene pairs showed modest statistical significance across several examples (Supplementary Fig. 6 ). From this analysis, we conclude that the Big Papi approach can identify hits consistently across sgRNA pairs.
Although some gene pairs, such as MAPK1-MAPK3 and BCL2L1-MCL1, showed strong effects in most cell lines, other interactions scored strongly in one cell line but were modest or absent in others (Fig. 4c) . We hypothesized that combining information across cell lines could improve detection of weaker but generalizable interactions, minimizing technical and cell-line-specific sources of variation; this proved an effective strategy (Supplementary Table 4 BRCA2  BRCA2  PARP1  MAP2K1  MAP2K1  MAP2K1  MAP2K2  MAP2K2  MAPK1  CHEK1  CHEK1  CHEK1  CHEK1  CHEK1  CHEK2  CHEK2  CHEK2  CHEK2  HSP90AA1  HSP90AA1  HSP90AA1  IMPDH1  IMPDH1  MTOR  UBB   AKT2  AKT3  AKT3  BCL2A1  BCL2L1  BCL2L10  BCL2L2  MCL1  BCL2L1  BCL2L10  BCL2L2  MCL1  BCL2L10  BCL2L2  MCL1  BCL2L2  MCL1  MCL1  BRCA2  PARP1  PARP2  PARP1  PARP2  PARP2  MAP2K2  MAPK1  MAPK3  MAPK1  MAPK3  MAPK3  CHEK2  HSP90AA1  IMPDH1  MTOR  WEE1  HSP90AA1  IMPDH1  MTOR  WEE1  IMPDH1  MTOR  WEE1  MTOR  WEE1  WEE1 By making some conservative assumptions about the correctness of particular subsets of synthetic lethal or buffering interactions, we were able to estimate in two independent ways true positive rates for the SynLet screens (Supplementary Discussion). Using these models, we calculated the true positive rate at different FDR thresholds for data from both individual cell lines as well as all leave-one-out iterations and obtained similar estimates whether based on synthetic lethal effects or on buffering interactions, suggesting the independent assumptions made for each were reasonable (Fig. 4e) . At an FDR threshold of 0.1, the empirically determined true positive rate ranged from 72-85%, not far from the theoretical value of 90% (i.e., 10% false discoveries).
Similarly, we modeled false negative rates based on conservative assumptions about same-gene buffering interactions (Supplementary Note 1). We observed a lower false negative rate when combining information from multiple cell lines (Fig. 4f) ; for example, at an FDR of 0.1, we determine a false negative rate of 57% when using individual cell lines, whereas combining five lines gives a false negative rate of 33%. Overall, the empirically determined true positive and false negative rates suggest that Big Papi is an efficient screening approach (Supplementary Fig. 7 ), especially when assayed across multiple cell lines.
Genetic interactions
We examined synthetic lethal interactions within the pre-defined groups across the six cell lines (Fig. 4c) . We did not observe a relationship between the putatively redundant genes UBB and UBC, despite analysis of buffering interactions indicating that the sgRNAs are active (Supplementary Fig. 7b ). Among the set of genes computationally predicted to engage in synthetic lethal interactions we did not observe strong interactions 27 . We note that these genes generally performed poorly in our analysis of buffering interactions ( Supplementary  Fig. 7b ) and thus may represent false negative findings. Combining information from all cell lines, however, identified an interaction between CHEK1 and WEE1 (FDR = 0.10), which has also been seen with small-molecule inhibitors 29 . The other four pre-defined groups revealed many interactions for further analysis and study.
Anti-apoptotic genes. In addition to the interaction between BCL2L1 and MCL1, synthetic lethality between BCL2L1 and BCL2L2 (Bcl-w) was detected in Meljuso, OVCAR8, and A375 at an FDR < 0.01, HT29 (0.03) and A549 (0.31). To the best of our knowledge, this interaction has not previously been observed. BCL2L2 is less studied than BCL2L1, with ~20-fold fewer publications indexed in PubMed. BCL2 is poorly expressed in these cells, but in Meljuso, with the highest expression, BCL2 interacted with BCL2L1 (FDR < 0.01) and MCL1 (0.20) (Fig. 5a) . We did not observe any strong interactions involving the genes encoding the anti-apoptotic proteins BCL2L10 and BCL2A1, despite high expression of the latter in some lines (Fig. 5a) .
We confirmed these interactions with small-molecule inhibitors. Meljuso, OVCAR8, and A549 cells were transduced with single SaCas9 sgRNAs targeting MCL1, BCL2L1, or BCL2L2, or controls. Cells were treated with various inhibitors of anti-apoptotic proteins: venetoclax, an FDA-approved BCL2 inhibitor 30 ; navitoclax, an extensively characterized inhibitor of BCL2, BCL2L1, and BCL2L2 31 , A-1331852 and WEHI-539, tool compounds described as BCL2L1 inhibitors 32, 33 ; and S63845, an MCL1 inhibitor in clinical development 34 . Cells were dosed from 1 nM to 1 µM, and cell viability assessed ( Fig. 5b  and Supplementary Fig. 8a ). Both sgRNAs targeting MCL1 strongly synergized with navitoclax, A-1331852, and WEHI-539; conversely, sgRNAs targeting BCL2L1 synergized specifically with S63845. Dual small-molecule treatment with A-1331852 and S63845 likewise synergized, with excess over Bliss independence scores of 85 or greater at combinations with 250 nM (Fig. 5c and Supplementary Fig. 8b) . Thus, small molecules confirmed the synthetic lethal interaction between MCL1 and BCL2L1.
MAPK genes. We detected a strong interaction between MAPK1 (ERK2) and MAPK3 (ERK1) in A375 (FDR = 0.04), A549 (<0.01), HT29 (<0.01), Meljuso (<0.01), and OVCAR8 (<0.01) (Fig. 4c) , all lines with activating mutations in the MAPK pathway (BRAF V600E; KRAS G12S; BRAF V600E; NRAS Q61L and HRAS G13D; and KRAS P121H, respectively). 786O cells, with no known mutations in the MAPK pathway, showed a weaker interaction (FDR = 0.57). MAP2K1 (MEK1) and MAP2K2 (MEK2) synergized in four of the five MAPK pathway mutant cell lines: HT29 (FDR = 0.01), OVCAR8 (0.05), Meljuso (0.06), and A549 (0.11). The exception, A375 (FDR = 1.0), was sensitive to loss of MAP2K1 individually (Fig. 3e) .
AKT genes. We saw a strong interaction for AKT1-AKT2 in HT29 cells (FDR < 0.01), the only line with a known PIK3CA mutation (P449T); the CDKO library also detected this interaction 8 . In contrast to the other five lines, HT29 cells express low levels of AKT3, potentially explaining the strong interaction (Fig. 5a) . Likewise, AKT1-AKT3 scored strongly in OVCAR8 cells (FDR = 0.13), which express the lowest levels of AKT2. However, the interaction between AKT2-AKT3 in Meljuso cells (FDR = 0.09) is not predicted based on AKT1 expression. Finally, we observe relationships across all three AKT genes in 786O cells, with moderate FDRs ranging from 0. 35-0.46 . No AKT isoforms show low expression in this line; thus, expression of one may partially compensate for loss of the other two. The relationships between AKT proteins are well-studied and complex, and they have both redundant and unique activities dependent on cellular context 35, 36 . Despite these differences across cell lines, combining information across all six lines gave FDRs of 0.04-0.12 (Fig. 4c) .
BRCA and PARP genes. We observed a relationship between PARP1-PARP2 in four cell lines: OVCAR8 (FDR = 0.06), A549 (0.07), A375 (0.12), and Meljuso (0.13), and across all cell lines (<0.01). Only OVCAR8 showed a strong interaction between BRCA2-PARP1 (FDR < 0.01); BRCA1 expression is lowest in these cells (Fig. 5a) . That the interactions across these genes was most pronounced in the ovarian line may have been anticipated, as PARP inhibitors have shown clinical efficacy in BRCA-deficient ovarian cancers 22 , although the dissimilar strength across cell lines for BRCA1-PARP1 may not have been expected. To further investigate, we performed a competition assay in three cell types: one that originally scored strongly (OVCAR8, FDR = 0.18), weakly (A375, 0.68), or was essentially null (Meljuso, 0.94). Here, EGFP + cells have dual knockout, whereas EGFP -cells are single knockouts of the gene targeted by the SaCas9 sgRNA; the relative viability of these populations can be monitored over time with flow cytometry (Fig. 5d) . In OVCAR8 and A375, double-knockout cells were strongly depleted relative to single knockouts, however the viability effect on double-knockout cells was notably weaker in Meljuso (Fig. 5e) . This result validates the interaction originally detected with weaker significance in A375 and demonstrates that Meljuso are indeed less sensitive to combinatorial BRCA1-PARP1 loss. Consistent with this, Shen-Mali classified BRCA1-PARP1 as a "private" synthetic lethal interaction in 293T cells but not A549 or Hela cells 7 , and BRCA mutant cells show varying sensitivity to PARP inhibitors both in cell culture and clinical settings 37, 38 .
Apoptosis screen
Interaction networks for pro-and anti-apoptotic genes have been assembled by biochemical approaches, and although some interactions are consistently detected, others show less consistent results 39 . Because pro-apoptotic genes were robust and reproducible hits in our initial screen, we investigated the apoptotic network further with a Big Papi screen. We selected 32 genes implicated in apoptosis and targeted them each with four sgRNAs, for a total of 20,736 perturbations including controls (Supplementary Table 5) ; sequencing of plasmid DNA gave an AUC of 0.67, with 73% of combinations present in the top 90% of reads.
We screened this library in Meljuso and OVCAR8 in duplicate for 21 d in standard growth conditions; further, in Meljuso we A r t i c l e s challenged the population with various inhibitors of anti-apoptotic proteins ( Fig. 6a and Supplementary Table 6 ). Knockout of some anti-apoptotic genes had minor growth effects, whereas knockout of pro-apoptotic genes did not decrease cell viability (Fig. 6b) . We analyzed these screens for synthetic lethal and buffering interactions, and confirmed a strong synthetic lethal interaction between BCL2L1 and both MCL1 and BCL2L2 (Supplementary Fig. 9 and Supplementary Table 7 ; this interaction was also observed above, Fig. 4 ). In both cell lines, we observed buffering interactions between pro-and anti-apoptotic genes (Fig. 6c) . The strongest interactions were detected between BCL2L1 and both BAK1 and BAX (FDR < 0.01 for combined data), multi-BH-domain proteins that direct mitochondrial outer membrane permeabilization (MOMP); interactions between these proteins have been detected biochemically 39 . BOK did not engage in strong interactions, potentially expected based on its low expression (Fig. 6d) . We next analyzed Meljuso cells screened with inhibitors, first examining single-gene effects. As expected, navitoclax and S63845 synergized with MCL1 and BCL2L1 knockout, respectively (Fig. 6e) . Knockout of BCL2A1, which did not show strong interactions when screened in standard growth conditions ( Fig. 4c and Supplementary Fig. 9 ), sensitized the cells to navitoclax. Conversely, knockout of BAX and PMAIP1
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To examine combinatorial phenotypes, we combined data across the three BCL2L1 inhibitors, to minimize effects due to molecule-specific mechanism of action. Whereas BAX-PMAIP1 knockout showed a minimal buffering interaction in standard growth conditions (FDR = 0.89), they synergized strongly to protect cells from death when treated with anti-apoptotic inhibitors (FDR < 0.01) (Fig. 6f) . Similarly, caspase-pro-apoptotic knockouts produced modest buffering interactions in standard growth conditions; only PMAIP1-CASP6 scored strongly (FDR = 0.12) (Fig. 6g) . However, inhibitors led to clearer detection of specific interactions. For example, the strongest initiator and effector caspases to interact with BAK1 were CASP8 (FDR = 0.10) and CASP6 (FDR = 0.01), respectively. These two caspases directly interact with each other 40 . Although caspase interactions are complex, CASP8 is generally associated with the extrinsic cell death pathway 41 . Conversely, BAX interacted strongly with CASP9 (FDR < 0.01) and CASP3 (FDR = 0.04), caspases with a well-established relationship 42 , with CASP9 associated most strongly with the mitochondrial cell death pathway. Although BAK1 and BAX are generally considered functionally redundant, differences in localization and binding partners have been documented 43, 44 ; to our knowledge this is the first report of differences in genetic interactions with downstream caspases in human cells.
Orthogonal activities
The Big Papi approach is readily applied to concomitant screening of orthogonal modalities (Fig. 7a) , for example, repressing one gene while activating another. To test the ability to combine distinct gene-targeting activities, we designed a Big Papi library to overexpress 38 annotated oncogenes with CRISPRa technology with three sgRNAs each, using a nuclease-dead SpCas9 (dCas9) fused to the "VPR" domain comprised of three transcriptional activators 45 . We employed SaCas9 to knockout 45 tumor suppressor genes, also with three sgRNAs each (Supplementary Table 8 ). With controls, the TsgOnco library totaled 19,250 constructs; pDNA sequencing gave an AUC of 0.63, and 77% of constructs were detected in the top 90% of reads. We screened HA1E cells, a kidney line immortalized by large T antigen, which inactivates TP53. After infection, cells were grown in standard conditions and on low-attachment culture plates (Fig. 7b) ; the latter are a surrogate for soft agar and select for transformation phenotypes 46 . We first examined performance of targeting sgRNAs paired with control sgRNAs, and observed good consistency, with overexpression of TP53 dramatically reducing viability with all three sgRNAs (Fig. 7c and Supplementary Table 9) . Likewise, SaCas9-mediated knockout of EEF2, CDK12, and ERCC2 decreased cell viability with all three sgRNAs for each gene (Fig. 7d) .
We next examined the data for genetic interactions ( Supplementary  Fig. 10) . A strong interaction was observed between dSpCas9-VPR sgRNAs targeting TP53 for overexpression, which is lethal, and SaCas9 sgRNAs targeting TP53 for knockout, which buffered this lethality. This effect was stronger in low attachment conditions, and serves as technical validation that overexpression and knockout are co-active in cells (Fig. 7e) . Several other interactions with TP53 overexpression were likewise more apparent in the stringent, low attachment conditions. Knockouts of both ZFHX3 (ATBF1) and CUX1, which had minimal effects on viability on their own, partially rescued the lethality caused by TP53 overexpression (Fig. 7f  and Supplementary Fig. 11 ). ZFHX3 directly interacts with TP53 to activate the CDKN1A promoter (p21 Cip1 ), leading to cell cycle arrest, and thus ZFHX3 loss buffers this TP53 activity 47 . Likewise, CUX1 deficiency activates PI3K signaling 48 ; consistent with this observation, knockout of PTEN increased proliferation, an effect that persisted in cells overexpressing TP53. Conversely, although KEAP1 knockout generally led to increased cell viability, this effect was muted upon A r t i c l e s TP53 overexpression (Fig. 7f) , which is consistent with the opposing actions of KEAP1 and TP53 on the transcription factor NFE2L2 (Nrf2). Normally, KEAP1 degrades NFE2L2, so KEAP1 loss leads to NFE2L2 stabilization; TP53 suppresses the metabolic target genes of NFE2L2, thereby nullifying the effect of KEAP1 knockout 49 . Notably, knockout of both CDKN2A (p16) and RB1 gave increased viability in the absence of TP53, but overexpression of TP53 reversed this phenotype. That these two genes are immediately upstream and downstream, respectively, of the cell cycle kinases CDK4 and CDK6 suggests this counterintuitive observation merits further exploration. These results serve as proof-of-principle demonstration that the Big Papi approach can combine multiple Cas9 activities in a single screen to reveal genetic interactions.
DISCUSSION
We developed a dual-Cas9 system to identify genetic interactions. This system is efficient, cost effective, and supports pooled library generation and screening. Synthetic lethal screens using our system identified interactions within several groups of functionally related genes, including the MAPK pathway, AKT signaling, DNA damage repair, and apoptosis, with high statistical confidence. We also applied this system to map buffering interactions between genes involved in apoptosis, both in standard growth conditions and in the presence of small molecules, which revealed additional genetic interactions. Finally, we combined CRISPR-mediated knockout and overexpression to uncover interactions with TP53.
SaCas9 has been used previously for in vivo gene editing 19, 20 and in an orthologous, chemically induced CRISPRa and CRISPRi system, although it was noted to have lower efficiency than SpCas9 in that study, most likely due to suboptimal sgRNA selection 50 . To increase SaCas9 utility, we assessed the activity of thousands of sgRNAs to define rules enabling selection of highly active sgRNAs. GUIDEseq results have shown that SaCas9 has fewer off-target effects than SpCas9, based on the modest sampling of sgRNAs assessed thus far by this technique 51 . These performance properties and the design rules provided here, coupled with its smaller size (~1 kilobase shorter than SpCas9), highlight SaCas9 as an attractive genome editing tool.
The number of genes that can be screened is typically limited by the scale of cell culture, which dictates the size of the library; generally, genome-wide single-gene sgRNA libraries contain ~100,000 perturbations and require 1,000 cells per perturbation. The Big Papi approach achieves reasonable performance with only two sgRNAs per gene (Supplementary Fig. 12) , and thus a screen to examine pairwise combinations of 158 genes with two sgRNAs per gene would have a similar number of perturbations: (158 × 2) × (158 × 2) = 99,856.
Our results highlight the importance of cell context in detecting interactions. With the SynLet library, no gene pair scored strongly (FDR < 0.01) in all six cell lines, and some showed strong interactions in only one line. One outlier was 786O, a renal clear cell carcinoma line with VHL deletion, in which we identified no synthetic lethal gene pairs at an FDR < 0.01. Biological replicates of the 786O screen were well-correlated, and we also detected buffering interactions when targeting the same gene with both Cas9s, suggesting that the screen was well-executed and the reagents were active. Heterogeneity of small molecules on different cell lines is well-documented and it is reasonable to expect the same heterogeneity across cell lines for genetic interactions. Although mutation status and mRNA expression could be used post facto to rationalize why some interactions were detected more strongly in some lines compared to others, combining information across cell lines proved a useful strategy for detecting generalizable interactions with increased confidence.
In summary, the Big Papi approach described here for dual-gene perturbation screens represents a powerful means to map genetic interactions in mammalian cells that can be applied across many biological questions and model systems.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METHODS
Vectors. Plasmids were cloned by synthesis and assembly (Genscript) and are available to the academic research community through Addgene:
pPapi (also known as pXPR_207): U6 and H1 promoters express two sgRNAs; short EF1a promoter (EFS) expresses SaCas9-2A-PuromycinR (Addgene 96921).
pXPR_034: U6 promoter expresses SaCas9 sgRNAs; EFS expresses SaCas9-2A-PuromycinR. An updated version of this plasmid with more convenient restriction sites, pXPR_206, has been deposited in Addgene (96920).
pLX_311-Cas9: SV40 promoter expresses blasticidin resistance; EF1a promoter expresses SpCas9 (generated by Sefi Rosenbluh, Hahn lab, Addgene 96924). pXPR_120: EF1a promoter expresses dSpCas9-VPR-2A-BlasticidinR (Addgene 96917).
Library production. Pooled libraries for expression of single sgRNAs were made as previously described, with oligonucleotide pools obtained from CustomArray 16 . For cloning of Big Papi pools, oligonucleotide inserts (Ultramers, IDT) were designed with 5′ BsmBI sites followed by 20 or 21 nt crRNA, 82 nt tracrRNA, 6 nt barcode, and 17 nt complementary sequence ( Fig. 1a and Supplementary Note 1) . The oligonucleotides for SpCas9 sgRNAs and SaCas9 sgRNAs were separately mixed together at a concentration of 5 µM each. 10 µL of each pool of oligonucleotides was then combined in a 100 µL reaction and extended using NEBNext (New England Biolabs) with an annealing temperature of 48 °C. The resulting dsDNA was purified by spin-column then ligated into the BsmBI-digested pPapi vector using 100 cycles of Golden Gate assembly with 100 ng insert and 500 ng vector using Esp3I and T7 ligase, as we have done previously for single sgRNA pools. The DNA was isopropanol precipitated and electroporated into STBL4 cells. A zero-generation (G0) plasmid DNA pool was then amplified by a second electroporation into STBL4 cells to create the G1 plasmid DNA pool, which was then used for virus production. We note that individual constructs to express two sgRNAs can be constructed either by the overlap-extension of individual oligonucleotides or by the use of gBlocks (IDT), which may be a more cost-effective option.
Virus production. For individual virus production: 24 h before transfection, HEK293T cells were seeded in 6-well dishes at a density of 1.5 × 10 6 cells per well in 2 mL of DMEM + 10% FBS. Transfection was performed using TransIT-LT1 (Mirus) transfection reagent according to the manufacturer's protocol. In brief, one solution of Opti-MEM (Corning, 66.25 µL) and LT1 (8.75 µL) was combined with a DNA mixture of the packaging plasmid pCMV_VSVG (Addgene 8454, 250 ng), psPAX2 (Addgene 12260, 1,250 ng), and the sgRNAcontaining vector (e.g., pPapi, 1,250 ng). The two solutions were incubated at room temperature for 20-30 min, during which time the HEK293T cells were replenished with fresh media. After this incubation, the transfection mixture was added dropwise to the surface of the HEK293T cells, and the plates were centrifuged at 1,000g for 30 min. Following centrifugation, plates were transferred to a 37 °C incubator for 6-8 h, then the media was removed and replaced with media supplemented with 1% BSA. A larger-scale procedure was used for production of the sgRNA library; 24 h before transfection, 18 × 10 6 HEK293T cells were seeded in a 175 cm 2 tissue culture flask, with transfection performed as described above using 6mL of Opti-MEM and 300 µL of LT1. Flasks were transferred to a 37 °C incubator for 6-8 h, then media aspirated and replaced with BSA-supplemented media. Virus was harvested 36 h after this media change.
Cell culture. A375, HT29, OVCAR8, 786O, A549, and Meljuso cells were obtained from the Cancer Cell Line Encyclopedia; HA1E cells were obtained from the Connectivity Map; HEK293T cells were obtained from ATCC (CRL-3216). All cell lines were routinely tested for mycoplasma contamination and maintained in a 37 °C humidity-controlled incubator with 5.0% CO 2. Cells were maintained in exponential phase growth by passaging every 2 or 3 d. Cell lines were maintained without antibiotics and supplemented with 1% penicillin/streptomycin during screens. Cas9 derivatives were made by transducing with the lentiviral vector pLX_311-Cas9, which expresses blasticidin resistance from the SV40 promoter and Cas9 from the EF1α promoter, as described previously 18 . The following list includes, respectively, cell line, media, and concentration of puromycin, blasticidin, and polybrene: A375; RPMI + 10% FBS; 1 µg/ml; 5 µg/ml; 1 µg/ml. HEK293T; DMEM + 10% FBS; 1 µg/ml; 5 µg/ml; 1 µg/ml. HT29; DMEM + 10% FBS; 2 µg/ml; 5 µg/ml; 1 µg/ml. MOLM13; RPMI + 10% FBS; 2 µg/ml; 5 µg/ml; 4 µg/ml. Meljuso; RPMI + 10% FBS; 1 µg/mL; 2 µg/mL; 4 µg/mL A549; DMEM + 10% FBS; 1.5 µg/mL; 5 µg/mL; 1 µg/mL OVCAR8; RPMI + 10% FBS; 2 µg/mL; 3 µg/mL; 4 µg/mL 786O; RPMI + 10% FBS; 1 µg/mL; 2 µg/mL; 4 µg/mL HA1E; MEM-alpha + 10% FBS; 1 µg/mL; 8 µg/mL; 4 µg/mL Flow cytometry. For experiments carried out in Figure 1 and Supplementary  Figure 2 , A375 cells stably expressing SpCas9 and GFP were transduced at an MOI of ~1 in 12-well plates. Two days after transduction, cells were selected with puromycin (1µg/mL) for 5 d. Cells were stained with APC-conjugated CD81 antibody (Biolegend 349510) diluted 1:100 in flow buffer (PBS, 2% FBS, 5µM EDTA) for 30 min on ice. Residual antibody was removed with two flow buffer washes, and cells were re-suspended in flow buffer. Flow cytometry was performed on the BDAccuri C6 Sampler system. Live cell populations were gated using forward and side scatter to exclude debris. CD81 + and EGFP + gates were set using non-transduced A375-SpCas9-EGFP cells.
SaCas9 activity rules.
Computational modeling for SaCas9 activity was done as previously for SpCas9 16 . In contrast to our previous work, we did not use the NGGX interaction feature (which is SpCas9 PAM-specific). Also, previously we generated two models for SpCas9, one which used gene positional features (nucleotide cut, percent peptide), and one that omitted them. We have since found the latter to be used more frequently, as it does not assume the target DNA encodes a protein, and thus we did not use gene positional features for the derivation of the SaCas9 activity model.
SynLet library screening.
To determine lentiviral titer, cell lines were transduced in 12-well plates with 150, 300, 500, and 800 µL virus with 3.0 × 10 6 cells per well in the presence of polybrene. The plates were centrifuged at 640g for 2 h then transferred to a 37 °C incubator for 4-6 h. Each well was then trypsinized, and an equal number of cells seeded into each of two wells of a 6-well dish. Two days post-transduction, puromycin was added to one well out of the pair. After 5 d, both wells were counted for viability by trypan exclusion. A viral dose resulting in 30-50% transduction efficiency, corresponding to an MOI of ~0.35-0.70, was used for subsequent library screening. Prior to screening-scale transduction, Cas9-expressing cell lines were selected with blasticidin then transduced in two or three biological replicates; puromycin selection began 2 d post-transduction. Transductions were performed with enough cells to achieve a representation of at least 500 cells per sgRNA per replicate, taking into account a 30-50% transduction efficiency. Puromycin selection was maintained for 5-7 d. Throughout the screen, cells were split at a density to maintain a representation of at least 500 cells per sgRNA. Cell counts were taken at each passage to monitor growth. After this screen, cells were pelleted by centrifugation, resuspended in PBS, and frozen promptly for genomic DNA isolation.
Genomic DNA preparation and sequencing. Genomic DNA (gDNA) was isolated using the QIAamp DNA Blood Midi Kit (Qiagen) as per the manufacturer's instructions. The concentration of these preparations was determined by UV spectroscopy (Nanodrop). PCR of single sgRNA expressing vectors was as described 16 . For the pPapi vector, dual sgRNA cassettes and plasmid DNA were PCR-amplified and barcoded with sequencing adaptors using ExTaq DNA Polymerase (Clontech), following the same procedure. Primer sequences (IDT) can be found in Supplementary Note 1. Amplified samples were then purified with Agencourt AMPure XP SPRI beads (Beckman Coulter, A63880) according to manufacturer's instructions and sequenced on a NextSeq sequencer (Illumina) with 300 nt single-end reads, with a 10% spike-in of PhiX DNA. Deconvolution of single sgRNA expressing vectors was as described 16 . For the pPapi vector, reads of the first sgRNA were counted by first searching in the sequencing read for CACCG, the part of the vector sequence that immediately precedes the 20-nucleotide U6 promoter-driven SpCas9 sgRNA.
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Describe the software used to analyze the data in this study.
False discovery rates of screens were determined using customized code that is made available on Github. GraphPad PRISM was used for small-scale comparisons between groups (e.g. Fig. 7e , and similar)
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
All generally-useful plasmids are available via Addgene.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
All antibodies were first compared to unstained cells. A reduction in signal after application of CRISPR technology is an excellent way to confirm the specificity of an antibody. No cell lines used are in this database.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
no animals
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Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
no humans
